A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.
There is no standard of care for elderly patients (age>or=70 years) with newly diagnosed glioblastoma (GBM). In 15 consecutive patients (median age 79 years) treated with temozolomide (TMZ) (42 days on; 14 days off), median survival was 6 months (range 4-14 months). This pilot study suggests that low dose daily TMZ may represent an alternative and equally effective treatment to more traditionally administered radiotherapy.
Chamberlain
Marc C
MC
Department of Interdisciplinary Oncology, Moffitt Cancer Center and Research Institute, 12902 Magnolia Avenue, Tampa, FL 33612-0804, USA. ChambeMC@moffitt.usf.edu
Chalmers
Lisa
L
D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D010865:Pilot Projects; D011379:Prognosis; D015996:Survival Rate; D000077204:Temozolomide; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide